Phase 2 Trial of Pembrolizumab To Prevent Recurrence in Head and Neck Cancer

Share this content:
Researchers are evaluating whether intravenous pembrolizumab will improve PFS among patients with head and neck cancer at high risk of recurrence.
Researchers are evaluating whether intravenous pembrolizumab will improve PFS among patients with head and neck cancer at high risk of recurrence.

Title: A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study1

Principal Investigators: Tanguy Seiwert, MD, University of Chicago

Description: For this randomized, phase 2 study, researchers are evaluating whether intravenous pembrolizumab will improve progression-free survival (PFS) among patients with head and neck cancer at high risk of recurrence.

All enrolled patients will have squamous cell carcinoma of the head and neck treated with curative intent.

The study has 2 arms: in the first, patients will receive pembrolizumab 200 mg every 3 weeks for 1 year; in the second, patients will receive placebo intravenously every 3 weeks for 1 year.

The primary endpoint is 2-year PFS. Secondary outcomes include PFS in PD-L1-positive patients and overall survival.

The estimated enrollment is 100 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02841748.

Status: This study is open and recruiting patients as of July 14, 2017.

This study is sponsored by the University of Chicago.

Reference

  1. Clinicaltrials.gov. A randomized, double-blind phase II study of adjuvant pembrolizumab versus placebo in head and neck cancers at high risk for recurrence- the PATHWay study.  NCT02841748. https://clinicaltrials.gov/ct2/show/NCT02841748. Accessed July 14, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters